EGFR and cancer: Looking specifically at the acquired drug resistance of EGFR tyrosine kinase inhibitors (TKIs) in NSCLC, it has been shown that inhibition of NF-κB is sufficient to reduce the viability of cancer cells that have adapted to EGFR TKIs [86].